sutures newsletter

PRODUCED BY AND FOR MEMBERS OF THE DEPARTMENT OF SURGERY December 2017 | Archived Issues

FDA Issues Alert About Risks of Febuxostat

The U.S. Food and Drug Administration is alerting the public that preliminary results from a safety clinical trial show an increased risk of heart-related death with febuxostat (Uloric) compared to another gout medicine called allopurinol. Healthcare professionals should consider this safety information when deciding whether to prescribe or continue patients on febuxostat.

The FDA website has more information.